Biotechnology was dramatically rewarded in the financial markets through much of 2020 and the first half of 2021, widely credited for providing the COVID-19 vaccines. This followed four already exceptional years in the financial markets, with the Nasdaq Biotech Index (NBI) hitting its all-time high of 5449.32 on 30 August 2021.
Our species – modern humans, or homo sapiens sapiens – has ever striven for progress. And progress was greatly enabled by fire, a fundamental chemical phenomenon that allows the fast release of large amounts of energy.
Healthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?
Fossil carbon is in nearly everything we use in our daily lives ranging from power and fuels to fibers, coatings, and materials used in our clothes, packaging, toys, and household goods. Virgin fossil carbon use in these products is not sustainable given the current understanding of the impact of extracted, emitted, and waste carbon on our environment, climate, and vulnerable populations.
COVID-19 is the acute pandemic, while antimicrobial resistance (AMR) is a silent, pandemic. New data makes the AMR pandemic visible, with the first global study of AMR estimating that 1.27 million people die from AMR every year, making AMR the 12th-leading cause of death globally.
While the Nasdaq Biotechnology index saw a huge uplift during the pandemic (+ 77% since March 2020 until reaching a peak in August 2021), it lost 27% during the last six months vs a 11%/4% decline for the Nasdaq Composite and the S&P 500, respectively
The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy
US Life Science leaders pledge to economically disengage from Russia.
The pharmaceutical industry has made significant advances in collaboration over the past two years, and I have seen many examples amongst Pistoia Alliance members of the power of cooperative working. It is imperative that the industry continues to build on these successes.